In MB and in primitive neuroectodermal tumors (PNET), the granzyme inhibitors SERPINB1 and SERPINB4 were acquired in 23% and 50% of the MB, respectively, while PNETs expressed SERPINB9, SERPINB1, and SERPINB4 in 29%, 29%, and 57% of the tumors [68,69]. Here, SERPINB9 is linked to primitive neuroectodermal tumor.